Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in v...
BACKGROUND: Patients with peritoneal metastases from colorectal cancer have a poor prognosis. If the...
(1) Background: Peritoneal metastasis in gastric cancer is associated with a poor prognosis. Complet...
peer reviewedUp to now, the prognosis of peritoneal carcinomatosis from GI tract cancers remains ver...
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritone...
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritone...
Peritoneal metastasis (PM) originating from gastrointestinal and gynecological malignancies are asso...
Peritoneal metastasis (PM) originating from gastrointestinal and gynecological malignancies are asso...
Hyperthermic intraperitoneal chemotherapy (HIPEC) is performed with a wide variation in methodology,...
With increasing awareness amongst physicians and improved radiological imaging techniques, the perit...
Objectives: In our study, we aimed to (1) create a peritoneal metastasis (PM) model in nude mice, ad...
Simple Summary Patients with cancer of the digestive system or ovarian cancer are at risk of develop...
Simple Summary Patients with cancer of the digestive system or ovarian cancer are at risk of develop...
Background: Cytoreductive surgery (CRS), followed by hyperthermic intraperitoneal chemotherapy (HIPE...
OBJECTIVE: Hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C can improve survival i...
HIPEC is a great treatment option to cure GI and ovarian cancers at advanced stages. Also it improve...
BACKGROUND: Patients with peritoneal metastases from colorectal cancer have a poor prognosis. If the...
(1) Background: Peritoneal metastasis in gastric cancer is associated with a poor prognosis. Complet...
peer reviewedUp to now, the prognosis of peritoneal carcinomatosis from GI tract cancers remains ver...
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritone...
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritone...
Peritoneal metastasis (PM) originating from gastrointestinal and gynecological malignancies are asso...
Peritoneal metastasis (PM) originating from gastrointestinal and gynecological malignancies are asso...
Hyperthermic intraperitoneal chemotherapy (HIPEC) is performed with a wide variation in methodology,...
With increasing awareness amongst physicians and improved radiological imaging techniques, the perit...
Objectives: In our study, we aimed to (1) create a peritoneal metastasis (PM) model in nude mice, ad...
Simple Summary Patients with cancer of the digestive system or ovarian cancer are at risk of develop...
Simple Summary Patients with cancer of the digestive system or ovarian cancer are at risk of develop...
Background: Cytoreductive surgery (CRS), followed by hyperthermic intraperitoneal chemotherapy (HIPE...
OBJECTIVE: Hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C can improve survival i...
HIPEC is a great treatment option to cure GI and ovarian cancers at advanced stages. Also it improve...
BACKGROUND: Patients with peritoneal metastases from colorectal cancer have a poor prognosis. If the...
(1) Background: Peritoneal metastasis in gastric cancer is associated with a poor prognosis. Complet...
peer reviewedUp to now, the prognosis of peritoneal carcinomatosis from GI tract cancers remains ver...